Review



pima cd4 platform  (Abbott Laboratories)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Abbott Laboratories pima cd4 platform
    Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect <t>CD4</t> testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.
    Pima Cd4 Platform, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pima cd4 platform/product/Abbott Laboratories
    Average 86 stars, based on 1 article reviews
    pima cd4 platform - by Bioz Stars, 2026-05
    86/100 stars

    Images

    1) Product Images from "A cluster randomized trial of Visitect CD4 Advanced Disease platform among outpatients with advanced HIV disease in Uganda"

    Article Title: A cluster randomized trial of Visitect CD4 Advanced Disease platform among outpatients with advanced HIV disease in Uganda

    Journal: Journal of the International AIDS Society

    doi: 10.1002/jia2.70075

    Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect CD4 testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.
    Figure Legend Snippet: Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect CD4 testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.

    Techniques Used:

    Time to ART initiation by CD4 group among participants who were ART naive. The left panel includes all participants. The right panel includes only participants with a confirmed CD4 result ≤200 cells/µl. Overall, median time to ART initiation, estimated from the Kaplan−Meier curve, was 0 days (95% CI, 0–1) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. In the Visitect CD4 arm, 54% of participants started ART on the day of enrolment; in the standard CD4 testing arm, 46% of participants started ART on the day of enrolment. Among participants with only advanced HIV disease (CD4 ≤200 cells/µl), median time to ART initiation was 5 days (95% CI, 0–10) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. Abbreviation: ART, antiretroviral therapy.
    Figure Legend Snippet: Time to ART initiation by CD4 group among participants who were ART naive. The left panel includes all participants. The right panel includes only participants with a confirmed CD4 result ≤200 cells/µl. Overall, median time to ART initiation, estimated from the Kaplan−Meier curve, was 0 days (95% CI, 0–1) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. In the Visitect CD4 arm, 54% of participants started ART on the day of enrolment; in the standard CD4 testing arm, 46% of participants started ART on the day of enrolment. Among participants with only advanced HIV disease (CD4 ≤200 cells/µl), median time to ART initiation was 5 days (95% CI, 0–10) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. Abbreviation: ART, antiretroviral therapy.

    Techniques Used:



    Similar Products

    pima cd4 platform  (Abbott Laboratories)
    86
    Abbott Laboratories pima cd4 platform
    Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect <t>CD4</t> testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.
    Pima Cd4 Platform, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pima cd4 platform/product/Abbott Laboratories
    Average 86 stars, based on 1 article reviews
    pima cd4 platform - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    pima cd4 analyser  (Abbott Laboratories)
    86
    Abbott Laboratories pima cd4 analyser
    Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect <t>CD4</t> testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.
    Pima Cd4 Analyser, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pima cd4 analyser/product/Abbott Laboratories
    Average 86 stars, based on 1 article reviews
    pima cd4 analyser - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    pima cd4 test machine  (Abbott Laboratories)
    86
    Abbott Laboratories pima cd4 test machine
    Figure 1 legend : <t>CD4</t> counts by near point of care quantitative device performed by nurses (CD4 count on y axis) and by semiquantitative LFA by HIV diagnostic assistants (color of point). Horizontal lines indicate various CD4 cell counts. Light shaded dots show concordant results; discordant results are shown as dark shaded dots. Results for six participants with CD4 >1000 (all concordant) are not shown on graph.
    Pima Cd4 Test Machine, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pima cd4 test machine/product/Abbott Laboratories
    Average 86 stars, based on 1 article reviews
    pima cd4 test machine - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    cd4 count pima  (Abbott Laboratories)
    86
    Abbott Laboratories cd4 count pima
    Figure 1 legend : <t>CD4</t> counts by near point of care quantitative device performed by nurses (CD4 count on y axis) and by semiquantitative LFA by HIV diagnostic assistants (color of point). Horizontal lines indicate various CD4 cell counts. Light shaded dots show concordant results; discordant results are shown as dark shaded dots. Results for six participants with CD4 >1000 (all concordant) are not shown on graph.
    Cd4 Count Pima, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd4 count pima/product/Abbott Laboratories
    Average 86 stars, based on 1 article reviews
    cd4 count pima - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    abbott cd4 pima analyzer  (Abbott Laboratories)
    86
    Abbott Laboratories abbott cd4 pima analyzer
    Figure 1 legend : <t>CD4</t> counts by near point of care quantitative device performed by nurses (CD4 count on y axis) and by semiquantitative LFA by HIV diagnostic assistants (color of point). Horizontal lines indicate various CD4 cell counts. Light shaded dots show concordant results; discordant results are shown as dark shaded dots. Results for six participants with CD4 >1000 (all concordant) are not shown on graph.
    Abbott Cd4 Pima Analyzer, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/abbott cd4 pima analyzer/product/Abbott Laboratories
    Average 86 stars, based on 1 article reviews
    abbott cd4 pima analyzer - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    pima cd4  (Abbott Laboratories)
    86
    Abbott Laboratories pima cd4
    Figure 1 legend : <t>CD4</t> counts by near point of care quantitative device performed by nurses (CD4 count on y axis) and by semiquantitative LFA by HIV diagnostic assistants (color of point). Horizontal lines indicate various CD4 cell counts. Light shaded dots show concordant results; discordant results are shown as dark shaded dots. Results for six participants with CD4 >1000 (all concordant) are not shown on graph.
    Pima Cd4, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pima cd4/product/Abbott Laboratories
    Average 86 stars, based on 1 article reviews
    pima cd4 - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    pima cd4 point-of-care assays  (Abbott Laboratories)
    90
    Abbott Laboratories pima cd4 point-of-care assays
    Figure 1 legend : <t>CD4</t> counts by near point of care quantitative device performed by nurses (CD4 count on y axis) and by semiquantitative LFA by HIV diagnostic assistants (color of point). Horizontal lines indicate various CD4 cell counts. Light shaded dots show concordant results; discordant results are shown as dark shaded dots. Results for six participants with CD4 >1000 (all concordant) are not shown on graph.
    Pima Cd4 Point Of Care Assays, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pima cd4 point-of-care assays/product/Abbott Laboratories
    Average 90 stars, based on 1 article reviews
    pima cd4 point-of-care assays - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    pima cd4 analyzer  (Abbott Laboratories)
    90
    Abbott Laboratories pima cd4 analyzer
    Figure 1 legend : <t>CD4</t> counts by near point of care quantitative device performed by nurses (CD4 count on y axis) and by semiquantitative LFA by HIV diagnostic assistants (color of point). Horizontal lines indicate various CD4 cell counts. Light shaded dots show concordant results; discordant results are shown as dark shaded dots. Results for six participants with CD4 >1000 (all concordant) are not shown on graph.
    Pima Cd4 Analyzer, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pima cd4 analyzer/product/Abbott Laboratories
    Average 90 stars, based on 1 article reviews
    pima cd4 analyzer - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect CD4 testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.

    Journal: Journal of the International AIDS Society

    Article Title: A cluster randomized trial of Visitect CD4 Advanced Disease platform among outpatients with advanced HIV disease in Uganda

    doi: 10.1002/jia2.70075

    Figure Lengend Snippet: Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect CD4 testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.

    Article Snippet: Several devices for point‐of‐care CD4 testing are commercially available, including the BD FACSPresto system (BD Biosciences, Franklin Lakes, NJ, USA) and the PIMA CD4 platform (Abbott, Chicago, IL, USA).

    Techniques:

    Time to ART initiation by CD4 group among participants who were ART naive. The left panel includes all participants. The right panel includes only participants with a confirmed CD4 result ≤200 cells/µl. Overall, median time to ART initiation, estimated from the Kaplan−Meier curve, was 0 days (95% CI, 0–1) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. In the Visitect CD4 arm, 54% of participants started ART on the day of enrolment; in the standard CD4 testing arm, 46% of participants started ART on the day of enrolment. Among participants with only advanced HIV disease (CD4 ≤200 cells/µl), median time to ART initiation was 5 days (95% CI, 0–10) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. Abbreviation: ART, antiretroviral therapy.

    Journal: Journal of the International AIDS Society

    Article Title: A cluster randomized trial of Visitect CD4 Advanced Disease platform among outpatients with advanced HIV disease in Uganda

    doi: 10.1002/jia2.70075

    Figure Lengend Snippet: Time to ART initiation by CD4 group among participants who were ART naive. The left panel includes all participants. The right panel includes only participants with a confirmed CD4 result ≤200 cells/µl. Overall, median time to ART initiation, estimated from the Kaplan−Meier curve, was 0 days (95% CI, 0–1) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. In the Visitect CD4 arm, 54% of participants started ART on the day of enrolment; in the standard CD4 testing arm, 46% of participants started ART on the day of enrolment. Among participants with only advanced HIV disease (CD4 ≤200 cells/µl), median time to ART initiation was 5 days (95% CI, 0–10) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. Abbreviation: ART, antiretroviral therapy.

    Article Snippet: Several devices for point‐of‐care CD4 testing are commercially available, including the BD FACSPresto system (BD Biosciences, Franklin Lakes, NJ, USA) and the PIMA CD4 platform (Abbott, Chicago, IL, USA).

    Techniques:

    Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect CD4 testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.

    Journal: Journal of the International AIDS Society

    Article Title: A cluster randomized trial of Visitect CD4 Advanced Disease platform among outpatients with advanced HIV disease in Uganda

    doi: 10.1002/jia2.70075

    Figure Lengend Snippet: Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect CD4 testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.

    Article Snippet: The most common methods of standard CD4 testing were the PIMA CD4 Analyser (Abbott) and BD FACSPresto (BD Biosciences).

    Techniques:

    Time to ART initiation by CD4 group among participants who were ART naive. The left panel includes all participants. The right panel includes only participants with a confirmed CD4 result ≤200 cells/µl. Overall, median time to ART initiation, estimated from the Kaplan−Meier curve, was 0 days (95% CI, 0–1) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. In the Visitect CD4 arm, 54% of participants started ART on the day of enrolment; in the standard CD4 testing arm, 46% of participants started ART on the day of enrolment. Among participants with only advanced HIV disease (CD4 ≤200 cells/µl), median time to ART initiation was 5 days (95% CI, 0–10) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. Abbreviation: ART, antiretroviral therapy.

    Journal: Journal of the International AIDS Society

    Article Title: A cluster randomized trial of Visitect CD4 Advanced Disease platform among outpatients with advanced HIV disease in Uganda

    doi: 10.1002/jia2.70075

    Figure Lengend Snippet: Time to ART initiation by CD4 group among participants who were ART naive. The left panel includes all participants. The right panel includes only participants with a confirmed CD4 result ≤200 cells/µl. Overall, median time to ART initiation, estimated from the Kaplan−Meier curve, was 0 days (95% CI, 0–1) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. In the Visitect CD4 arm, 54% of participants started ART on the day of enrolment; in the standard CD4 testing arm, 46% of participants started ART on the day of enrolment. Among participants with only advanced HIV disease (CD4 ≤200 cells/µl), median time to ART initiation was 5 days (95% CI, 0–10) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. Abbreviation: ART, antiretroviral therapy.

    Article Snippet: The most common methods of standard CD4 testing were the PIMA CD4 Analyser (Abbott) and BD FACSPresto (BD Biosciences).

    Techniques:

    Figure 1 legend : CD4 counts by near point of care quantitative device performed by nurses (CD4 count on y axis) and by semiquantitative LFA by HIV diagnostic assistants (color of point). Horizontal lines indicate various CD4 cell counts. Light shaded dots show concordant results; discordant results are shown as dark shaded dots. Results for six participants with CD4 >1000 (all concordant) are not shown on graph.

    Journal: medRxiv

    Article Title: High performance of CD4 rapid testing by lay providers in Malawi: Results from a prospective diagnostic accuracy study supporting decentralized advanced HIV disease screening

    doi: 10.64898/2026.01.07.26343324

    Figure Lengend Snippet: Figure 1 legend : CD4 counts by near point of care quantitative device performed by nurses (CD4 count on y axis) and by semiquantitative LFA by HIV diagnostic assistants (color of point). Horizontal lines indicate various CD4 cell counts. Light shaded dots show concordant results; discordant results are shown as dark shaded dots. Results for six participants with CD4 >1000 (all concordant) are not shown on graph.

    Article Snippet: The semi-quantitative LFA used was VISITECT®CD4 test product (Accubio, UK) [11,14), the quantitative near point of care device-based test was the PIMA CD4 test machine (Abbott, USA).

    Techniques: Diagnostic Assay

    Journal: medRxiv

    Article Title: High performance of CD4 rapid testing by lay providers in Malawi: Results from a prospective diagnostic accuracy study supporting decentralized advanced HIV disease screening

    doi: 10.64898/2026.01.07.26343324

    Figure Lengend Snippet:

    Article Snippet: The semi-quantitative LFA used was VISITECT®CD4 test product (Accubio, UK) [11,14), the quantitative near point of care device-based test was the PIMA CD4 test machine (Abbott, USA).

    Techniques: Diagnostic Assay